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https://doi.org/1Background: Heart failure (HF) and cancer are a significant cause of morbidity and mortality in the US.
Due to overlapping risk factors, these two conditions often coexist.
Methods: We sought to describe the national burden of HF for hospitalized patients with cancer. We iden-
tified adults admitted with a primary oncologic diagnosis in 2014 included in the National Inpatient Sample
(NIS). Patient hospitalizations were divided based on presence or absence of comorbid HF. Primary out-
comes included cost, length of stay (LOS), and inpatient mortality. Logistic regression analysis with cluster
adjustment was performed to determine predictors of inpatient mortality.
Results: There were 834,900 admissions for a primary oncologic diagnosis in patients without comorbid HF,
and 64,740 (7.2%) admissions for patients with comorbid HF. Patients with HF were on average older and
had more comorbidities. Patients with HF had significantly higher mean hospitalization cost ($22,571 vs
$20,234, p-value <0.001), age-standardized LOS (12.7 vs 8.2 days, p-value <0.001), and age-standardized
inpatient mortality (12.2% vs 4.5%, p-value <0.001). Presence of HF predicted inpatient mortality after
adjusting for age, race, insurance payer, and comorbidity index (OR 1.12, 95% CI 1.04-20, p-value = 0.002).
Conclusion: Patients with cancer hospitalized with comorbid HF represent a high-risk population with
increased costs and high inpatient mortality rates. More data is needed to determine what screening and
treatment measures may improve outcomes (J Cardiac Fail 2019;25:516521)
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516Heart disease and cancer share multiple risk factors, such as
age, tobacco use, diet, and lack of physical activity, and there-
fore the 2 conditions frequently coexist. In addition, many
effective and life-prolonging chemotherapeutic agents may
result in substantial cardiotoxicity leading to symptoms of car-
diac dysfunction.3 Over the past several years, the field of car-
dio-oncology has emerged with the aim of addressing the
specific health needs of patients with cancer who are either at
cardiovascular risk or have preexisting heart disease. The pop-
ulation of cardio-oncologic patients is expected to increase in
the near future owing to our aging population. By the year
2030, the prevalence of HF is expected to increase by 46%,
resulting in >8 million adults with HF.2 Similarly, by 2020,
the number of cancer survivors is projected to increase from
11.7 million in 2007 to 18 million.4 Although multiple studies
have evaluated the effects of comorbidities on the prognosis
of various cancer diagnoses, none to our knowledge have spe-
cifically described the relationship between HF and the out-
comes of patients with cancer hospitalized in the US.
Understanding this relationship may provide insights and
Outcomes in Patients with Cancer and Heart Failure  Tuzovic et al 517opportunities for improving care of patients with cancer. The
present study explores the risk of comorbid HF on hospital-
ized patients with cancer. We describe the national burden of
HF as well as characterize the hospital events, procedures,
and outcomes for hospitalized patients with cancer.Methods
The National Inpatient Sample (NIS) from the Agency
for Healthcare Quality and Research (AHRQ) Health Care
Utilization Project (HCUP) provides a representative sam-
ple of hospitalization administrative data in the US. For
2014, 20% of the 4,411 HCUP-participating hospitals were
sampled, constituting an unweighted sample of >7 million
hospitalizations. The unit of analysis in the NIS is a dis-
charge; therefore, readmissions are not identified. The NIS
sampling frame covers >95% of the United States popula-
tion and >94% of all community hospital discharges.5
All adult (age 18 y) patient hospitalizations with a pri-
mary cancer diagnosis were selected according to the Clini-
cal Classification Software (CCS) principal diagnostic
codes (online Supplemental Table 1). The CCS was devel-
oped by AHRQ as part of the HCUP to collapse Interna-
tional Classification of Diseases, 9th revision, clinical
modification (ICD-9-CM) codes into clinically meaningful
and more useable categories.6 There were 16 cancer diagno-
ses in total: head and neck, gastrointestinal (GI), lung,
breast, female reproductive system, male reproductive sys-
tem, renal, bladder, thyroid, Hodgkin lymphoma, non-
Hodgkin lymphoma, leukemia, multiple myeloma, central
nervous system (CNS), melanoma, and other unclassified
malignancies. Patients with one of the following CCS codes
were included in the “other cancer” category: 1) cancer,
other and unspecified primary; 2) malignant neoplasm with-
out specification of site; or 3) neoplasms of unspecified
nature or uncertain behavior. In an effort to exclude elective
admissions for low-risk surgical procedures, admissions
categorized as elective and lasting <48 hours in duration
requiring surgical procedures were removed from the sam-
ple. Hospitalizations for primary oncologic conditions were
categorized into 2 groups, those without comorbid HF and
those with HF, to compare patient and hospitalization char-
acteristics between cohorts (online Supplemental Table 2).
Selected comorbidities and inpatient procedures were iden-
tified according to relevant ICD-9-CM codes.
Outcomes of interest included hospitalization costs,
length of stay (LOS), postdischarge disposition, and inpa-
tient mortality. To characterize utilization of hospital serv-
ices further, rates of multiple inpatient events were
calculated including procedures and the diagnosis of circu-
latory shock. Procedures included were blood transfusions,
inpatient chemotherapy, cardiac catheterization, dialysis,
mechanical ventilation, continuous positive airway pres-
sure, thoracentesis, tracheostomy, and bronchoscopy.
Analyses of the patient characteristics and hospitalization
costs accounted for the survey design of the NIS. Patient
characteristics for the sample were described accountingfor survey weights and clustering of data to make national
estimates. Differences between groups were tested with the
use of t tests and chi-square tests as indicated by baseline
characteristics. For the cost analysis, the NIS provides total
charges, which reflect the amount a hospital billed for serv-
ices, rather than actual costs or the amount a hospital
received in reimbursement. To calculate costs, HCUP pro-
vides cost-to-charge ratio (CCR) adjustments.7 A known
limitation of hospital-specific CCRs is that they do not
account for all cost variations derived from hospital
charges.8 Cost-to-charge estimation is improved with fur-
ther adjustment accounting for specific diagnosis-related
groups.9 The NIS CCR costs were further adjusted with the
appropriate adjustment factor for each discharge’s Medi-
care severity diagnosis-related groups or CCS category to
obtain the final hospitalization cost estimates.8 Differences
between the groups were compared with the use of t tests or
chi-square tests as indicated.
Multivariable logistic regression analysis was performed
to identify factors associated with inpatient mortality. Mod-
els accounted for NIS survey design and clustering and
adjusted for age, sex, race/ethnicity, median household
income, comorbid HF, Elixhauser comorbidity score, and
the cancer type with the use of multivariable fractional pol-
ynomials for continuous risk factors. A graph of the curvi-
linear risk association between age and inpatient mortality,
and between Elixhauser composite score and inpatient mor-
tality is included in online Supplemental Figs. 1 and 2. The
inpatient mortality odds ratios (ORs) based on cancer type
were calculated with respect to a reference category, which
was defined as the cancer type associated with the lowest
inpatient mortality rate. Analyses were performed in Stata
15.1 (Statacorp, College Station, Texas). All estimation
procedures were performed with the use of appropriate NIS
survey weights to account for sampling design, and results
are presented as the weighted national 2014 hospitalized
population with the use of the Stata svyset estimation proce-
dures. The Institutional Review Board provided exemption
for this project.10
Results
In total, there were 899,640 hospitalizations with a pri-
mary oncologic diagnosis in 2014. Of those, 834,900
(92.8%) patient hospitalizations did not have documented
comorbid HF and 64,740 (7.2%) documented a comorbid
HF diagnosis. Patient characteristics are presented in
Table 1. Patients with HF were on average older than
patients without HF (73.7 y vs 63.9 y). Patients with HF
had more documented comorbidities during the hospitaliza-
tion overall, with particularly high rates of hypertension
(74.1% vs 53.1%; P < .001), coronary artery disease
(46.0% vs 13.1%; P < .001), and diabetes mellitus (40.3%
vs 23.4%; P < .001) compared with patients without HF.
The most common oncologic diagnoses in patients with HF
and without HF were GI (25.6% vs 26.1%; P = .2713), lung
(17.7% vs 13.1%; P < .001), and other (24.4% vs 25.3%;
P = .0542).
Table 1. Characteristics of Patients Admitted With Primary
Cancer Diagnoses by Heart Failure Status
Characteristic
No Heart
Failure
Heart
Failure P Value
Total no. of patients 834,900 (92.8%) 64,740 (7.2%) <.001
Age (SD), y 63.9 (14.1) 73.7 (11.3) <.001
<65 49.3% 20.6%
6575 29.2% 31.4%
>75 21.5% 48.0%
Female 50.2% 46.3% <.001
Race <.001
White 67.7% 71.6%
African American 12.1% 14.1%
Hispanic 8.5% 5.3%
Asian 3.2% 1.6%
Primary payer <.001
Medicare 49.4% 77.3%
Medicaid 11.6% 5.6%
Private 32.7% 13.5%
Self-pay 2.9% 1.3%
Cancer types
Head and neck 2.9% 1.8% <.001
GI (esophagus, stomach,
colon, rectum and anus,
liver, pancreas, other GI
organs)
26.1% 25.6% .2713
Lung (bronchus lung,
other respiratory)
13.1% 17.7% <.001
Breast 2.7% 1.9% <.001
Uterine (uterus, cervix,
ovary, other female geni-
tal organs)
5.6% 3.8% <.001
Male genital (testicular
and other male genital)
2.3% 1.4% <.001
Renal (kidney and other
urinary)
4.1% 4.0% .6729
Bladder 2.7% 4.1% <.001
Thyroid 0.8% 0.4% <.001
Hodgkin lymphoma 0.4% 0.2% .0009
Non-Hodgkin lymphoma 3.8% 4.7% <.001
Leukemia 3.8% 5.5% <.001
Multiple myeloma 1.9% 2.5% <.001
CNS 3.3% 1.1% <.001
Melanoma 0.2% 0.1% .1640
Other 25.3% 24.4% .0542
Comorbidities
CAD 13.1% 46.0% <.001
Atrial fibrillation 8.7% 36.0% <.001
HTN 53.1% 74.1% <.001
DM 23.4% 40.3% <.001
CKD 7.9% 27.3% <.001
COPD 14.6% 31.0% <.001
Liver disease 4.4% 4.7% .0398
Acute Stroke 1.6% 1.7% .4981
CAD, coronary artery disease; CKD, chronic kidney disease; CNS, cen-
tral nervous system; COPD, chronic obstructive pulmonary disease; DM,
diabetes mellitus; GI, gastrointestinal; HTN, hypertension.
Table 2. Age-Standardized and Unadjusted Clinical and
Economic Outcomes
Outcome
No Heart
Failure
Heart
Failure P Value
Unadjusted
Median adjusted cost $13,878 $14,450
Mean adjusted cost $20,234 $22,571 <.001
Median (IQR) length of stay 5 (39) 7 (411)
Mean length of stay 7.4 9.2 <.001
Inpatient mortality 5.5% 10.1% <.001
Age-standardized
Mean adjusted cost $25,157 $39,053 <.001
Mean length of stay 8.2 12.7 <.001
Inpatient mortality 4.5% 12.2% <.001
Disposition <.001
Home/routine 54.7% 33.4%
Home health care 22.0% 26.1%
Skilled nursing facility 14.8% 27.5%
IQR, interquartile range.
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and disposition data are reported in Table 2. The hospitali-
zation cost and LOS for patients with HF were significantly
higher than in patients without HF (mean adjusted cost
$22,571 vs $20,234 [P < .001]; mean age-standardized
LOS 12.7 d vs 8.2 d [P < .001]). The age-standardized
inpatient mortality was 12.2% for patients with HF com-
pared with 4.5% for patients without HF (P < .001).
Patients with HF were more often discharged to a skilled
nursing facility than patients without HF (27.5% vs 14.8%).Overall, the age-standardized rates of circulatory shock
and most inpatient procedures were higher in patients with
HF than without HF (Table 3). Otherwise, differences in
inpatient chemotherapy and tracheostomies were not
markedly different.
Patient factors associated with inpatient mortality are
presented in Table 4. Female sex was protective against
inpatient mortality (OR 0.89, 95% confidence interval [CI]
0.850.93; P < .001). Presence of HF was associated with
a higher risk of inpatient mortality (OR 1.12, 95% CI
1.041.20; P < .001). Adjusted ORs were most significant
for the following cancers: lung (OR 4.67, 95% CI
2.967.37; P < .001), breast (OR 3.74, 95% CI 2.355.97,
P < .001), non-Hodgkin lymphoma (OR 3.72, 95% CI
2.355.89; P < .001), and leukemia (OR 7.53, 95% CI
4.7911.86; P < .001).
Discussion
This study describes the clinical characteristics, inpatient
events, and outcomes of hospitalized patients with cancer
and HF. Comorbid HF affects many patients with cancer
(7.2%) who are admitted to the hospital with a primary
oncologic diagnosis. Patients with cancer who have comor-
bid HF tend to be older, and commonly have a number of
other comorbidities, including coronary artery disease,
atrial fibrillation, hypertension, diabetes mellitus, chronic
kidney disease, and chronic obstructive pulmonary disease.
A comorbid HF diagnosis is associated with increased cost
of hospitalization, LOS, and, most strikingly, a high inpa-
tient mortality rate of 12.2%.
Comorbidities are important modifiers for the treatment and
prognosis of cancer. Presence of multiple comorbidities has
been associated with worse outcomes in multiple cancers,
including breast cancer,11 colon cancer,12 and lung cancer.13
For example, Yancik et al11 evaluated the effects of comorbid-
ities in 1,800 postmenopausal breast cancer patients. They
found that comorbid conditions, such as diabetes, renal failure,
stroke, liver disease, previous cancer, and smoking, predicted
Table 3. Inpatient Procedure Rates by Heart Failure Status for Primary Cancer-Related Hospitalizations
No Heart Failure Heart Failure
Procedure Crude Age-standardized* Crude Age-Standardized* P Valuey
Shock 1.6% 1.5% 3.9% 10.7% <.001
Procedures
Blood Transfusions 16.0% 17.2% 26.0% 31.6% <.001
Chemotherapy 6.7% 12.0% 6.3% 18.9% .1153
Cardiac Catheterization 0.2% 0.1% 1.5% 2.5% <.001
Dialysis 1.1% 0.9% 4.1% 8.1% <.001
Mechanical Ventilation 4.5% 4.2% 11.3% 15.7% <.001
CPAP 1.2% 1.0% 4.3% 4.4% <.001
Thoracentesis 6.8% 5.6% 12.8% 11.4% <.001
Tracheostomy 1.4% 1.3% 1.3% 2.0% .2205
Bronchoscopy 7.8% 5.5% 9.6% 9.1% <.001
CPAP, continuous positive airway pressure.
*Age standardization to 2000 US Standard Population.
yP values estimated from crude proportions.
Table 4. Patient Factors Associated With Inpatient Mortality
During a Primary Cancer-Related Hospitalization
Factor OR* 95% CI P Value
Female 0.89 0.850.93 <.001
Heart failure 1.12 1.041.20 .002
Cancer type
Thyroid ref.
Head and neck 1.71 1.052.78 .032
GI (esophagus, stomach, colon,
rectum and anus, liver, pancreas,
other GI organs)
2.52 1.603.97 <.001
Lung (bronchus lung, other
respiratory)
4.67 2.967.37 <.001
Breast 3.74 2.355.97 <.001
Uterine (uterus, cervix, ovary,
other female genital organs)
2.03 1.273.25 .003
Male genital (testicular and other
male genital)
1.78 1.082.93 .023
Renal (kidney and other urinary) 1.13 0.691.83 .631
Bladder 1.55 0.962.51 .075
Hodgkin lymphoma 2.87 1.605.15 <.001
Non-Hodgkin lymphoma 3.72 2.355.89 <.001
Leukemia 7.53 4.7911.86 <.001
Multiple myeloma 3.14 1.945.08 .004
CNS 2.03 1.253.30 <.001
Melanoma 5.66 3.1610.12 <.001
Other 3.43 2.185.39 <.001
CI, confidence interval; CNS, central nervous system; GI, gastrointesti-
nal; OR, odds ratio.
*Adjusted for age and Elixhauser comorbidity scores using multivari-
able fractional polynomials, as well as race, insurance payer, and median
house income.
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most common cause of death after cancer was heart disease
(17.1% of all deaths). They concluded that both age and
comorbidity status influence the ability to obtain adequate can-
cer prognostic information, limit treatment options, and
increase the chance of dying from a nononcologic cause. In
less aggressive cancers, comorbidity plays an even larger role
in predicting survival.14
To our knowledge, the present study is the first to evalu-
ate and characterize the national burden of HF among hos-
pitalized oncologic patients. We found that the inpatient
mortality rate of patients with cancer and HF (12.2%) iswell above the average mortality rate of patients of a similar
age admitted with acute decompensated HF (»4% mortality
rate)15; however, it is similar to the rate of inpatient mortal-
ity for HF patients who required treatment in the intensive
care unit (»11% mortality rate).15 HF may influence mor-
tality rates for a number of reasons. First, as previously
mentioned, HF alone is a significant cause of morbidity and
mortality and can carry a prognosis similar to many
cancers.16,17 In addition, HF often limits cancer treatment
options because many chemotherapeutic regimens exacer-
bate or even cause cardiac dysfunction and acute cardiovas-
cular events. For example, anthracyclines, trastuzumab,
cyclophosphamide, 5-fluorouracil, and certain tyrosine
kinase inhibitors all have a significant incidence of HF.3
Other chemotherapeutic agents, such as cisplatin, nilotinib,
and paclitaxel, are associated with acute coronary artery
thrombosis.18 Patients who receive suboptimal chemother-
apy because of preexisting HF or from developing cardio-
toxicity during treatment can be at high risk for poor
outcomes.
Increasing efforts are being made to optimize the care of
patients with cancer who have cardiovascular disease or
have multiple cardiovascular risk factors both before and
after cancer treatment. The American Heart Association
recently published a scientific statement highlighting the pre-
ventive and treatment strategies for cardiovascular disease in
breast cancer patients.19 Recommendations for surveillance
with the use of echocardiography and strain imaging for can-
cer patients receiving cardiotoxic chemotherapy have
recently been published by the American Society of Echocar-
diography and the American Society of Clinical Oncology,
which reflects the growing efforts to identify patients at risk
for poor cardiac outcomes.20,21 Although progress has been
made in recognizing the specific care needs of patients with
cancer and comorbid cardiac disease, cardiovascular man-
agement of a patient with cancer continues to be complex
because it depends on the type of cancer and the cardiotoxic-
ity profile of the chemotherapeutic regimen as well as the
patient’s preexisting cardiovascular risk factors. In the pres-
ent study, we show that hospitalized patients with cancer and
520 Journal of Cardiac Failure Vol. 25 No. 7 July 2019HF have poor outcomes, thus highlighting a potential oppor-
tunity for improvement in multidisciplinary care.
Future research is essential to better understand how to
screen and manage hospitalized high-risk patients with
cancer. Whereas our analysis of the NIS database is based
on administrative data, a clinical registry of patients may
offer opportunities to analyze the correlation of hospitali-
zation outcomes with biomarker profiles and specific che-
motherapeutic agents. Similarly, the Nationwide
Readmissions Database enables analyses of national read-
mission rates and can be used for future studies evaluating
the effect of HF on readmission rates for cancer patients.
The utility of simple interventions, such as early screening
with cardiac biomarkers or imaging, or early involvement
of the cardiology consulting team for hospitalized cancer
patients with high cardiovascular risk, also warrants evalu-
ation.
Study Limitations
These data represent hospitalization episodes and not
unique patients. The diagnostic codes used to identify HF
are highly specific with reasonable sensitivity (»65%) and
a positive predictive value of »84%.22 A clinical registry
or cohort study may improve sensitivity to screen relevant
patients for HF but would not provide the national scale of
information provided through the NIS. This is a known
shortcoming of administrative data from real-world
patients. The NIS samples administrative data, so more
detailed data regarding symptoms, vital signs, chemother-
apeutic agents, and laboratory data are not available. In
addition, data on HF etiology, ejection fraction, functional
status, and medical therapy are not available. There are
significant limitations regarding the diagnosis of cancer,
the stage of disease, and time in the clinical course (newly
diagnosed and localized vs advanced disease after multiple
treatments). Patients with certain cancer diagnoses may be
at a greater risk of mortality because of the intensity and
modalities of therapy, and this information is not captured
in the NIS database. The accuracy of diagnoses is depen-
dent upon medical provider coding and certain diagnoses
may be undercoded to a greater degree. Cost estimates are
derived based on HCUP methodology and may not be
accurate of true hospitalization costs. Although we used
Elixhauser comorbidity scores to adjust for comorbid fac-
tors associated with HF, other conditions prevalent among
HF patients may impart risk to oncologic patients which
were not accounted for in the inpatient mortality regres-
sion model.
Conclusion
This study shows that cancer patients admitted to the hos-
pital who have comorbid HF have higher costs, longer LOS,
and high risk of short-term mortality. Prospective longitudi-
nal studies are needed to further assess the additional bur-
den of HF in cancer patients. It is unclear whether earlier
recognition and treatment of HF can affect outcomes, butthis warrants further investigation with a collaborative
effort between oncologists and cardiologists.
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